We're almost there! #LALCA26 and #ITMIG26 begin November 12 in São Paulo. Join thoracic oncology experts for the latest research, scientific discussions, and opportunities to connect. There's still time to register: bit.ly/4e72Zm4

🔥IASLC #AI Artificial Intelligence Taskforce Survey 🆙 @IASLC #AI Taskforce ☑️Leads: @mihaela_aldea @SeastedtMD Dr. Muhammad Rafiqul Islam 🎯Parallel, mutually complementary surveys for physicians and patients 🎯Addressing global challenges in AI accessibility ▶️Patient: iaslc.co1.qualtrics.com/jfe/… ▶️Physician: iaslc.co1.qualtrics.com/jfe/… #LCSM @OncoAlert @Larvol @EGFRResisters @ALKPositiveinc @ros1cancer @KRASKickers @Exon20Group @RETRenegades @metcrusaders *Image Created by @HHorinouchi with Gemini

During #WCLC26, experts outlined important takeaways from the 9th Edition TNM Classification, as well as future directions. 🔗 Read the recap in ILCN: bit.ly/47NfmQL #LCSM

Happy 52nd Birthday, IASLC! 🎉 52 years of bringing together the global community dedicated to advancing lung cancer research and improving patient care. From all of us on the IASLC Communications Committee, we're happy to celebrate this milestone and proud to help share the science, stories, and achievements of this incredible community! Here's to many more years of collaboration and progress together! @IASLC @MattSmeltzer #IASLC #LungCancer #LungCancerResearch

I had so much fun recording #WCLC26 highlights in Arabic alongside wonderful colleagues from Palestine, Jordan, Egypt, Australia and USA 🌍🎙

🌍 #WCLC26 highlights, now in Arabic! In the latest #LungCancerConsidered episode, host Dr. @NaglaAKarimMD is joined by Drs. Bashir Abu Aqeel, @AlrabiKamal, Riad Abdel Jalil, Ahmed Magdy Rabea, Myriam Saadi, and Hussein Soudy to revisit highlights from the 2026 World Conference on Lung Cancer. 🎧 Listen to the episode: bit.ly/4i8tvgc #LungCancer #ThoracicOncology

Pulmonary large cell neuroendocrine carcinoma is clinically and molecularly distinct from small cell #lungcancer. In this large retrospective series, Choudhury et al. found that there is no clear association of benefit observed through the application of molecularly classified standard treatments of patients with LCNEC. Guidelines for the development of prospective trials of novel therapeutics may be helpful here. Read more: bit.ly/4z1rE3R #LungCancerResearch #JTO

What matters most to the #radiology community? IASLC is seeking input from radiology professionals to help guide future education, research, leadership and networking opportunities. Take our brief survey: bit.ly/4yaE1JV

From attending IASLC meetings as a postdoctoral fellow to serving on our Board of Directors, what a journey! As we celebrate 52 years of IASLC, @triparnasen shares how the organization has shaped her career and the special connections that make our global community so meaningful. Here's to the people, partnerships, and shared passion that have made 52 years of progress possible! 🎂 #IASLC52 #ThoracicOncology

🎂 IASLC turns 52 today, and we're celebrating with a gift! Never been an IASLC member? Claim a FREE Associate Membership with code [IASLCBirthday2026]. Join our global thoracic oncology community! Access your membership: bit.ly/4iFRpB8 #IASLC52

One more chance to show off your IASLC knowledge! We're wrapping up our 52nd birthday trivia celebration with one final question! 🎂 Think you know the answer? Reply below for a chance to win IASLC merch! Good luck! #IASLC52

🎧 #WCLC26 insights from Taiwan! Dr. Kuan-Yu Chen joins Drs. Bin-Chi Liao, Mong-Wei Lin & Po-Lan Su for a Mandarin-language discussion of key conference highlights. Listen: bit.ly/3UAtEkJ #LungCancerConsidered #LungCancer #ThoracicOncology #Mandarin

⏰ The IASLC Guidelines Survey closes today! Help us better understand how thoracic cancer clinical guidelines are used in practice and where challenges remain. Share your perspective: bit.ly/4jIYsd7

🔬 Pumitamig plus elfe-D demonstrated encouraging early efficacy in SCLC across all lines of therapy and dose levels. 🔗 Read the insights from a #WCLC26 presentation by @AdamJSchoenfeld in ILCN: bit.ly/4hLUSxC #LCSM

🎉 52 years of advancing #lungcancer research, education, and collaboration! As we celebrate IASLC's upcoming birthday, we're putting your knowledge to the test! Think you know the answer to our latest trivia question? 🤔 Reply below to enter our IASLC merch drawing! #IASLC52

🎂 IASLC is turning 52, and we're celebrating the lead-up to our birthday with some trivia! Think you know IASLC's history? Reply with your answer to our trivia question below to be entered into a drawing for IASLC merch! 🎁 Let's celebrate 52 years together! 🎉 #IASLC52

I am looking forward to connecting with colleagues across Latin America and advancing care for our patients with thoracic cancers. See you there at the LALCA & ITMIG 2026 Conference, November 12–14 in São Paulo, Brazil. See you there! #LALCA26 @WinshipAtEmory @IASLC

VIKTOR is evolving! 🤖 First launched in 2025, IASLC's thoracic oncology knowledge platform now offers new capabilities with VIKTOR 2.0, including natural language searching, expanded cell line data, and AI-supported knowledge access. Exclusive to full IASLC members. Explore now: iaslc.org/viktor

Trade the winter chill for Scottsdale sunshine! ☀️ Join us Dec. 4–6 at #NACLC26 for the latest thoracic oncology research, clinical insights, and opportunities to connect with colleagues. Register: bit.ly/3VHjvD7 #LungCancer

After developing digital machine learning models to quantify tumor bed area and residual viable tumor, Dacic et al. compared these results to previously published assessments of pathological response from pathologists from the IASLC's reproducibility study. Their findings support the utility of machine learning algorithms for evaluating pathological response in patients with NSCLC. Read the report: bit.ly/3VEKNKq #LungCancerResearch #JTO